The study will evaluate the role of adding azithromycin to topical treatment in patients with mild to moderate atopic dermatitis
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
40
Topical treatment will be applied, Betamethasone or tacrolimus ointments
Azithromycin will be combined with topical treatment
Cairo University
Cairo, Saray, Egypt
Improvement in Eczema Area and Severity Index (EASI)
The primary outcome will be the change in the Eczema Area and Severity Index (EASI) score from baseline to the end of the treatment period. The EASI is a validated clinician-assessed tool that evaluates the severity and extent of atopic dermatitis by assessing erythema, edema/papulation, excoriation, and lichenification across four body regions. Scores range from 0 to 72, with higher scores indicating more severe disease. Outcome variable: Mean change in EASI score from baseline. Assessment time points: Baseline, Week 2, Week 4, Week 8, and end of follow-up. Treatment response: Proportion of patients achieving EASI-50, EASI-75, and EASI-90 (≥50%, ≥75%, and ≥90% improvement from baseline).
Time frame: 3 months
Investigator's Global Assessment (IGA)
The Investigator's Global Assessment will be used to evaluate the overall clinical severity of atopic dermatitis. Scale: 0 = Clear 1. = Almost clear 2. = Mild 3. = Moderate 4. = Severe Outcome variables: Mean change in IGA score. Percentage of patients achieving IGA 0/1 (clear or almost clear).
Time frame: 4 months
Pruritus Severity
Pruritus will be assessed using a 10-cm Visual Analog Scale (VAS) or Numeric Rating Scale (NRS, 0-10). 0 = No itch 10 = Worst imaginable itch Outcome: Mean reduction in pruritus score.
Time frame: 3
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.